A comprehensive view of Fresenius Kabi AG. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Fresenius Kabi's Tyenne, a biosimilar tocilizumab drug for inflammatory and immune diseases referencing Actemra tocilizumab in both IV and subcutaneous formulations; this marks the company's third biosimilar approval in the US
Published: March 08, 2024 by ENP Newswire
Fresenius Medical recalls Sanxin single use sterile syringes due to potential leaks and presence of unknown black material; syringes used during hemodialysis treatments to draw heparin
Published: November 16, 2023 by ForeignAffairs.co.nz
Fresenius Kabi launches Plerixafor injection, a generic of Mozobil, in US in 24 mg per 1.2 mL single dose vial; Plerixafor used with granulocyte-colony stimulating factor to treat non-Hodgkin's lymphoma or multiple myeloma
Published: August 10, 2023 by ENP Newswire
Fresenius Kabi launches Fentanyl Citrate injection, USP in ready-to-administer prefilled syringes in the US; company is sole provider of a 100 mcg per 2 mL presentation in a manufacturer-prepared syringe
Published: July 12, 2023 by ENP Newswire
Fresenius Kabi, a provider of injectable medications, launches Rocuronium Bromide Injection with advanced RFID-enabled labels, its first product compatible with Bluesight’s KitCheck System, a kit and tray solution for hospitals allowing use of RFID
Published: May 24, 2023 by Kit Check Inc.

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count